L-LEUCYL-L-LEUCINE METHYL ESTER TREATMENT OF DONOR LYPMHOCYTE INFUSIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

摘要

The present invention relates to a kind of for inhibiting the method for the graft versus host disease in allogeneic hematopoietic stem cell to transplant the cytotoxic T cell that (HSCT) patient eliminates selection in donor lymphocyte infusion (DLI) by using L- leucyls-L-Leu methyl ester (LLME). LLME is shown as inhibiting GVHD in through the animal models selectively induced programmed cell death in natural killer cells and cytotoxic T cell. When removing the concentration needed for the GVHD- inducing T cells before implantation, when useparated marrows are processed, application to the LLME of the clinical HSCT situations of people, however, being interfered by HSC toxicity. In the present invention, this problem is avoided by managing the LLME ex vivo treatments of the DLI of the transplanting below for the HSC that immunocyte exhausts. In this setting, the effect on clinical of the LLME on HSC between DLI is the result is that incoherent. In another embodiment, after the separation of CD34+ the stem cells then common management of the processed donor CD34- scores of LLME and untreated CD34+ stem cells, the risk of toxicity of population of stem cells is avoided by the LLME processing of external donor lymphocyte.